Chemical Society Reviews,
Journal Year:
2024,
Volume and Issue:
53(19), P. 9582 - 9608
Published: Jan. 1, 2024
Targeted
protein
degradation
(TPD)
has
emerged
as
a
revolutionary
paradigm
in
drug
discovery
and
development,
offering
promising
avenue
to
tackle
challenging
therapeutic
targets.
Unlike
traditional
approaches
that
focus
on
inhibiting
function,
TPD
aims
eliminate
proteins
of
interest
(POIs)
using
modular
chimeric
structures.
This
is
achieved
through
the
utilization
proteolysis-targeting
chimeras
(PROTACs),
which
redirect
POIs
E3
ubiquitin
ligases,
rendering
them
for
by
cellular
ubiquitin-proteasome
system
(UPS).
Additionally,
other
technologies
such
lysosome-targeting
(LYTACs)
autophagy-based
degraders
facilitate
transportation
endo-lysosomal
or
autophagy-lysosomal
pathways
degradation,
respectively.
Despite
significant
growth
preclinical
research,
many
fail
progress
beyond
this
stage
development.
Various
factors
contribute
limited
success
agents,
including
hurdle
inadequate
delivery
target
site.
Integrating
into
platforms
could
surmount
challenges
Journal of the American Chemical Society,
Journal Year:
2023,
Volume and Issue:
145(22), P. 12193 - 12205
Published: May 19, 2023
Selenoprotein
plays
a
crucial
role
in
immune
cells
and
inflammatory
regulation.
However,
as
protein
drug
that
is
easily
denatured
or
degraded
the
acidic
environment
of
stomach,
efficient
oral
delivery
selenoprotein
great
challenge.
Herein,
we
innovated
an
hydrogel
microbeads-based
biochemical
strategy
can
situ
synthesize
selenoproteins,
therefore
bypassing
necessity
harsh
conditions
for
while
effectively
generating
selenoproteins
therapeutic
applications.
The
microbeads
were
synthesized
by
coating
hyaluronic
acid-modified
selenium
nanoparticles
with
protective
shell
calcium
alginate
(SA)
hydrogel.
We
tested
this
mice
bowel
disease
(IBD),
one
most
representative
diseases
related
to
intestinal
immunity
microbiota.
Our
results
revealed
microbeads-mediated
synthesis
could
prominently
reduce
proinflammatory
cytokines
secretion
mediate
(e.g.,
neutrophils
monocytes
increase
regulatory
T
cells)
relieve
colitis-associated
symptoms.
This
was
also
able
regulate
gut
microbiota
composition
(increase
probiotics
abundance
suppress
detrimental
communities)
maintain
homeostasis.
Considering
widely
associated
cancers,
infections,
inflammations,
etc.,
might
be
possibly
applied
broadly
tackle
various
diseases.
Journal of Nanobiotechnology,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: Jan. 3, 2024
Abstract
Successful
oral
insulin
administration
can
considerably
enhance
the
quality
of
life
(QOL)
diabetes
patients
who
must
frequently
take
injections.
Oral
administration,
on
other
hand,
is
seriously
hampered
by
gastrointestinal
enzymes,
wide
pH
range,
mucus
and
mucosal
layers,
which
limit
bioavailability
to
≤
2%.
Therefore,
a
large
number
technological
solutions
have
been
proposed
increase
insulin,
in
polymeric
nanoparticles
(PNPs)
are
highly
promising
for
delivery.
The
recently
published
research
articles
chosen
this
review
based
applications
PNPs
with
strong
future
potential
delivery,
do
not
cover
all
related
work.
In
review,
we
will
summarize
controlled
release
mechanisms
latest
delivery
nanocarrier,
challenges
prospect.
This
serve
as
guide
investigators
wish
engineer
study
systems.
Graphical
Nano Letters,
Journal Year:
2023,
Volume and Issue:
23(10), P. 4683 - 4692
Published: March 13, 2023
The
oral
delivery
of
probiotics
is
commonly
adopted
for
intestinal
disease
treatments
in
clinical
settings;
however,
the
suffer
from
a
strong
acidic
attack
gastric
area
and
low-efficiency
colonization
naked
probiotics.
Coating
living
with
synthetic
materials
has
proven
effective
enabling
adaption
bacteria
to
gastrointestinal
environments,
which,
unfortunately,
may
shield
initiating
therapeutic
responses.
In
this
study,
we
report
copolymer-modified
two-dimensional
H-silicene
nanomaterial
(termed
SiH@TPGS-PEI)
that
can
facilitate
adapt
diverse
microenvironments
on-demand.
Briefly,
SiH@TPGS-PEI
electrostatically
coated
on
surface
probiotic
helps
resist
erosive
destruction
stomach
spontaneously
degrades
by
reacting
water
generate
hydrogen,
an
anti-inflammatory
gas
response
neutral/weakly
alkaline
environment,
thus
exposing
colitis
amelioration.
This
strategy
shed
new
light
development
intelligent
self-adaptive
materials.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
36(6)
Published: Sept. 19, 2023
Abstract
Compared
to
injection
administration,
oral
administration
is
free
of
discomfort,
wound
infection,
and
complications
has
a
higher
compliance
rate
for
patients
with
diverse
diseases.
However,
reduces
the
bioavailability
medicines,
especially
biologics
(e.g.,
peptides,
proteins,
antibodies),
due
harsh
gastrointestinal
biological
barriers.
In
this
context,
development
prosperity
nanotechnology
have
helped
improve
bioactivity
availability
medicines.
On
basis,
first,
barriers
are
discussed,
then
nanomedicine
based
on
organic
inorganic
nanomaterials
their
biomedical
applications
in
diseases
reviewed.
Finally,
challenges
potential
opportunities
future
nanomedicine,
which
may
provide
vital
reference
eventual
clinical
transformation
standardized
production
put
forward.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
35(45)
Published: Aug. 7, 2023
Subcutaneous
(SC)
injection
is
a
common
administration
route
for
rapid
and
efficient
delivery
of
biotherapeutics.
However,
syringe-based
injections
usually
require
professional
assistance
are
associated
with
pain
potential
risks
infections,
thus
leading
to
undesired
patient
compliance
poor
life
quality.
Herein,
this
work
presents
an
ultrarapid-acting
microneedle
(URA-MN)
patch
immediate
transdermal
therapeutics
in
minimally
invasive
manner.
Effervescent
agents
incorporated
into
the
tip
URA-MN
generation
CO2
bubbles
upon
insertion
skin,
immediately
powering
biotherapeutics
release
within
few
minutes.
The
kinetics
diverse
including
liraglutide
(LRT),
insulin,
heparin
from
patches
evaluated
three
different
mouse
models,
potent
therapeutic
effects
achieved
only
5
min
administration.
Noteworthily,
attributed
short
application
duration
negligible
residuals
MN
matrix
remaining
shows
desirable
biocompatibility
after
six-week
Exploration,
Journal Year:
2024,
Volume and Issue:
4(5)
Published: March 5, 2024
Abstract
Inflammatory
bowel
disease
(IBD)
is
a
recurring
chronic
inflammatory
disease.
Current
treatment
strategies
are
aimed
at
alleviating
clinical
symptoms
and
associated
with
gastrointestinal
or
systemic
adverse
effects.
New
delivery
needed
for
the
of
IBD.
Bacteria
promising
biocarriers,
which
can
produce
drugs
in
situ
sense
gut
real
time.
Herein,
we
focus
on
recent
studies
engineered
bacteria
used
IBD
introduce
application
diagnosis.
On
this
basis,
current
dilemmas
future
developments
bacterial
systems
discussed.
